Search

Your search keyword '"Katie Jeffery"' showing total 84 results

Search Constraints

Start Over You searched for: Author "Katie Jeffery" Remove constraint Author: "Katie Jeffery" Topic business Remove constraint Topic: business
84 results on '"Katie Jeffery"'

Search Results

1. Planning for the emergence of vaccine-resistant SARS-CoV-2: addressing revaccination delivery bottlenecks

2. 14-year trends and resistance patterns of blood and cerebrospinal fluid cultures in children under three years old

3. Impaired antibody response to COVID‐19 vaccination in patients with chronic myeloid neoplasms

4. Hepatitis B virus (HBV) viral load, liver and renal function in adults treated with tenofovir disoproxil fumarate (TDF) vs. untreated: a retrospective longitudinal UK cohort study

5. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

6. Ten Years of Population-Level Genomic Escherichia coli and Klebsiella pneumoniae Serotype Surveillance Informs Vaccine Development for Invasive Infections

7. T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study

8. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study

9. Parenchymal involvement on CT pulmonary angiography in SARS-CoV-2 Alpha variant infection and correlation of COVID-19 CT severity score with clinical disease severity and short-term prognosis in a UK cohort

10. Transmission of community- and hospital-acquired SARS-CoV-2 in hospital settings in the UK: A cohort study

11. Epidemiological data and genome sequencing reveals that nosocomial transmission of SARS-CoV-2 is underestimated and mostly mediated by a small number of highly infectious individuals

12. Enhancing epidemiological investigation of nosocomial SARS-CoV-2 infection with whole genome sequencing: A retrospective cohort study across four hospitals in the UK

13. Molecular epidemiology and antimicrobial resistance phenotype of paediatric bloodstream infections caused by Gram-negative bacteria in Oxfordshire, UK

14. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

15. Divergent trajectories of antiviral memory after SARS-Cov-2 infection

16. Tropheryma whipplei endocarditis: An uncommon infection with potentially fatal consequences

18. Quantitative SARS-CoV-2 anti-spike responses to Pfizer–BioNTech and Oxford–AstraZeneca vaccines by previous infection status

19. A blood atlas of COVID-19 defines hallmarks of disease severity and specificity

20. Transmission dynamics of SARS-CoV-2 in the hospital setting

21. Quantitative SARS-CoV-2 anti-spike responses to Pfizer-BioNTech and Oxford-AstraZeneca vaccines by previous infection status

22. An observational cohort study on the incidence of SARS-CoV-2 infection and B.1.1.7 variant infection in healthcare workers by antibody and vaccination status

23. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

24. An Observational Cohort Study on the Incidence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and B.1.1.7 Variant Infection in Healthcare Workers by Antibody and Vaccination Status

25. Stringent thresholds in SARS-CoV-2 IgG assays lead to under-detection of mild infections

26. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

27. Natural and vaccine-induced antibody and cellular responses against emerging SARS-CoV-2 variants of concern

28. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial

29. Home-based SARS-CoV-2 lateral flow antigen testing in hospital workers

30. T-Cell and Antibody Responses to First BNT162b2 Vaccine Dose in Previously SARS-CoV-2-Infected and Infection-Naive UK Healthcare Workers: A Multicentre, Prospective, Observational Cohort Study

31. Sustained T Cell Immunity, Protection and Boosting Using Extended Dosing Intervals of BNT162b2 mRNA Vaccine

32. Azithromycin in Hospitalised Patients with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

33. Efficacy and safety of tenofovir disoproxil fumarate (TDF) in hepatitis B virus (HBV) monoinfection: longitudinal analysis of a UK cohort

34. Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison

35. Antibodies to SARS-CoV-2 are associated with protection against reinfection

36. The duration, dynamics and determinants of SARS-CoV-2 antibody responses in individual healthcare workers

37. CovidNudge: diagnostic accuracy of a novel lab-free point-of-care diagnostic for SARS-CoV-2

38. Author response: Differential occupational risks to healthcare workers from SARS-CoV-2 observed during a prospective observational study

39. Stringent thresholds for SARS-CoV-2 IgG assays result in under-detection of cases reporting loss of taste/smell

40. Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial

41. Ten years of population-level genomic Escherichia coli and Klebsiella pneumoniae serotype surveillance informs vaccine development for invasive infections

42. Rapid roll out of SARS-CoV-2 antibody testing—a concern

43. Effect of Dexamethasone in Hospitalized Patients with COVID-19 – Preliminary Report

44. SARS-CoV-2 RNA detected in blood samples from patients with COVID-19 is not associated with infectious virus

45. Antibody testing for COVID-19: A report from the National COVID Scientific Advisory Panel

46. Endemic hepatitis B virus (HBV) among hospital in-patients in Bangladesh, including evidence of occult infection

47. Challenges for NHS hospitals during covid-19 epidemic

48. Hepatitis C virus

49. SARS-CoV-2 antibody prevalence, titres and neutralising activity in an antenatal cohort, United Kingdom, 14 April to 15 June 2020

50. Assessing COVID-19 cohorting strategies in a UK district general hospital during the first wave of COVID-19

Catalog

Books, media, physical & digital resources